Top 3 Asian Penny Stocks With Market Caps Over US$100M To Watch

As global markets navigate a landscape of mixed economic signals, Asia continues to be a focal point for investors seeking opportunities in emerging sectors. Penny stocks, though an older term, still capture the essence of investing in smaller or newer companies that may offer significant growth potential. By focusing on those with strong financials and promising outlooks, investors can uncover valuable opportunities within this often-overlooked segment of the market.

Top 10 Penny Stocks In Asia

Click here to see the full list of 1,168 stocks from our Asian Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Zhejiang Shibao (SEHK:1057)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Zhejiang Shibao Company Limited, along with its subsidiaries, focuses on the research, design, development, production, and sale of automotive steering systems and accessories in China with a market cap of HK$8.58 billion.

Operations: Zhejiang Shibao Company Limited has not reported any specific revenue segments.

Market Cap: HK$8.58B

Zhejiang Shibao Company Limited has shown robust financial health and growth, with earnings increasing by 95.8% over the past year, surpassing industry averages. The company maintains a strong balance sheet with short-term assets of CN¥2.2 billion exceeding both short-term and long-term liabilities significantly, while operating cash flow comfortably covers its debt obligations. Recent earnings reports reflect substantial revenue growth from CNY 1,819.44 million to CNY 2,693.47 million year-on-year, alongside improved net profit margins from 4.6% to 6%. Additionally, the company announced a dividend increase for shareholders in May 2025.

• Jump into the full analysis health report here for a deeper understanding of Zhejiang Shibao.
• Understand Zhejiang Shibao's track record by examining our performance history report.

China Wantian Holdings (SEHK:1854)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: China Wantian Holdings Limited operates in the green food supply, catering chain, and environmental protection and technology sectors across the People’s Republic of China, Seychelles, Samoa, and the British Virgin Islands with a market cap of approximately HK$2.69 billion.

Operations: The company's revenue is primarily derived from food supply (HK$750.39 million), followed by catering services (HK$37.42 million) and environmental protection and technology services (HK$0.82 million).

Market Cap: HK$2.69B

China Wantian Holdings Limited operates with a market cap of approximately HK$2.69 billion, primarily generating revenue from its green food supply sector (HK$750.39 million). Despite being unprofitable with a net loss of HK$41.99 million for the year ended December 2024, the company has managed to reduce its debt to equity ratio significantly over five years, reflecting improved financial management. Short-term assets comfortably cover both short and long-term liabilities, providing some financial stability. Recent executive changes may impact strategic direction as Ms. Shum Ching Yee Jennifer brings extensive experience in corporate finance and accounting to her new roles within the company.

• Get an in-depth perspective on China Wantian Holdings' performance by reading our balance sheet health report here.
• Explore historical data to track China Wantian Holdings' performance over time in our past results report.

JW (Cayman) Therapeutics (SEHK:2126)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: JW (Cayman) Therapeutics Co. Ltd is a clinical stage cell therapy company focused on the research, development, manufacture, and marketing of cellular immunotherapy products in China, with a market cap of approximately HK$1.05 billion.

Operations: The company's revenue is primarily generated from its Pharmaceuticals segment, amounting to CN¥158.22 million.

Market Cap: HK$1.05B

JW (Cayman) Therapeutics, with a market cap of HK$1.05 billion, focuses on cellular immunotherapy in China and has reported CN¥158.22 million in revenue from its pharmaceutical segment. Despite being currently unprofitable, the company has improved its financial position by reducing losses over the past five years and maintaining more cash than debt. Recent developments include a significant product-related announcement where Carteyva® received acceptance for a supplemental Biological License Application as second-line treatment for relapsed or refractory large B-cell lymphoma, supported by promising clinical trial results showing high response rates and manageable side effects.

• Dive into the specifics of JW (Cayman) Therapeutics here with our thorough balance sheet health report.
• Examine JW (Cayman) Therapeutics' earnings growth report to understand how analysts expect it to perform.

Seize The Opportunity

• Investigate our full lineup of 1,168 Asian Penny Stocks right here.
• Want To Explore Some Alternatives? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com